TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been assigned an average recommendation of “Hold” from the six brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $6.00.

A number of brokerages recently weighed in on TCRX. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Tuesday, April 21st. Wedbush boosted their price target on shares of TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a research note on Thursday, March 5th. Finally, Wall Street Zen lowered TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday.

TScan Therapeutics Price Performance

TCRX opened at $1.18 on Tuesday. The stock’s 50-day moving average price is $1.12 and its 200 day moving average price is $1.13. TScan Therapeutics has a 12-month low of $0.88 and a 12-month high of $2.57. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.34. The firm has a market cap of $67.14 million, a price-to-earnings ratio of -1.23 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). The company had revenue of $0.98 million during the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%. As a group, sell-side analysts expect that TScan Therapeutics will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TCRX. Boothbay Fund Management LLC increased its stake in shares of TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after buying an additional 8,121 shares during the period. Panagora Asset Management Inc. acquired a new position in TScan Therapeutics during the 4th quarter worth approximately $25,000. HRT Financial LP purchased a new stake in shares of TScan Therapeutics in the 4th quarter valued at approximately $26,000. Voleon Capital Management LP purchased a new stake in shares of TScan Therapeutics in the 3rd quarter valued at approximately $87,000. Finally, Marshall Wace LLP acquired a new stake in shares of TScan Therapeutics in the 2nd quarter valued at $78,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.